JP2018537415A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537415A5
JP2018537415A5 JP2018519031A JP2018519031A JP2018537415A5 JP 2018537415 A5 JP2018537415 A5 JP 2018537415A5 JP 2018519031 A JP2018519031 A JP 2018519031A JP 2018519031 A JP2018519031 A JP 2018519031A JP 2018537415 A5 JP2018537415 A5 JP 2018537415A5
Authority
JP
Japan
Prior art keywords
polypeptide
antibody
multivalent
terminus
variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018519031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537415A (ja
JP6936497B2 (ja
Filing date
Publication date
Priority claimed from EP15189665.1A external-priority patent/EP3156417A1/en
Application filed filed Critical
Publication of JP2018537415A publication Critical patent/JP2018537415A/ja
Publication of JP2018537415A5 publication Critical patent/JP2018537415A5/ja
Application granted granted Critical
Publication of JP6936497B2 publication Critical patent/JP6936497B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018519031A 2015-10-13 2016-10-13 多価Ｆｖ抗体 Active JP6936497B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15189665.1A EP3156417A1 (en) 2015-10-13 2015-10-13 Multivalent fv antibodies
EP15189665.1 2015-10-13
PCT/EP2016/074642 WO2017064221A1 (en) 2015-10-13 2016-10-13 Multivalent fv antibodies

Publications (3)

Publication Number Publication Date
JP2018537415A JP2018537415A (ja) 2018-12-20
JP2018537415A5 true JP2018537415A5 (enExample) 2019-11-21
JP6936497B2 JP6936497B2 (ja) 2021-09-15

Family

ID=54325413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519031A Active JP6936497B2 (ja) 2015-10-13 2016-10-13 多価Ｆｖ抗体

Country Status (13)

Country Link
US (1) US11572415B2 (enExample)
EP (2) EP3156417A1 (enExample)
JP (1) JP6936497B2 (enExample)
KR (1) KR20180057720A (enExample)
CN (1) CN108473577A (enExample)
AU (1) AU2016336866B2 (enExample)
BR (1) BR112018007445A2 (enExample)
CA (1) CA3001765A1 (enExample)
IL (1) IL258638B2 (enExample)
MX (1) MX2018004547A (enExample)
SG (2) SG11201803083XA (enExample)
WO (1) WO2017064221A1 (enExample)
ZA (1) ZA201802543B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44381A (fr) 2015-06-15 2019-01-23 Numab Innovation Ag Format d'anticorps hétérodimères multispécifiques
AU2018295119B2 (en) * 2017-06-25 2024-10-03 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
JP7288913B2 (ja) 2018-03-14 2023-06-08 アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質
CN111527108A (zh) * 2018-03-27 2020-08-11 西雅图免疫公司 制导和导航控制蛋白的制造和使用方法
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies
BR112020020828A2 (pt) * 2018-04-13 2021-01-19 Affimed Gmbh Proteínas de ligação, composições farmacêuticas, método para o tratamento ou melhoria de uma doença, para tratar e/ou prevenir uma doença, para tratar um paciente e para tratar câncer e anticorpos
US20210179734A1 (en) * 2018-04-17 2021-06-17 Invenra Inc. Trivalent trispecific antibody constructs
AU2019327155A1 (en) 2018-08-27 2021-03-18 Affimed Gmbh Cryopreserved NK cells preloaded with an antibody construct
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子
CN118459602A (zh) * 2019-11-06 2024-08-09 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
EP4255931A1 (en) * 2020-12-03 2023-10-11 Amgen Inc. Immunoglobuline constructs with multiple binding domains
JP2024510098A (ja) * 2021-02-19 2024-03-06 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用
IL308154A (en) 2021-07-30 2023-12-01 Affimed Gmbh Double structure antibodies
IL311765A (en) * 2021-09-29 2024-05-01 Modex Therapeutics Inc Antigen-binding polypeptides, antigen-binding polypeptide complexes and methods of using them
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
US20230272069A1 (en) * 2022-02-28 2023-08-31 Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE69535719T2 (de) * 1994-01-07 2009-03-19 Mochida Pharmaceutical Co. Ltd. Fas-antigenbindender ligand
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
EP1294904A1 (en) * 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
ES2276735T3 (es) * 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
AU2002364531A1 (en) * 2001-12-26 2003-07-24 Ibc Pharmaceuticals Methods of generating multispecific, multivalent agents from vh and vl domains
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
CA2657385A1 (en) * 2006-07-13 2008-01-17 Naoki Kimura Cell death inducer
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2784631T3 (es) * 2012-12-03 2020-09-29 Novimmune Sa Anticuerpos anti-CD47 y métodos de uso de los mismos
WO2014106004A2 (en) 2012-12-28 2014-07-03 Abbvie, Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
US20150017120A1 (en) * 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
MA44381A (fr) * 2015-06-15 2019-01-23 Numab Innovation Ag Format d'anticorps hétérodimères multispécifiques

Similar Documents

Publication Publication Date Title
JP2018537415A5 (enExample)
JP2017176174A5 (enExample)
JP2016536322A5 (enExample)
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
PE20231851A1 (es) Proteinas que se unen a nkg2d, cd16 y clec12a
JP2017504578A5 (enExample)
AR077088A1 (es) Proteinas biespecificas de union a antigeno
WO2016207304A8 (en) Monoclonal anti-il-1racp antibodies
JP2014158485A5 (enExample)
JP2017529067A5 (enExample)
JP2014533239A5 (enExample)
JP2017513476A5 (enExample)
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
JP2020517287A5 (enExample)
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
AR108034A1 (es) Moléculas de unión a ror1, y métodos de uso de las mismas
HRP20171608T1 (hr) Protutijela koja vežu albumin i njihovi vezujući fragmenti
JP2016531924A5 (enExample)
JP2016525551A5 (enExample)
AR076797A1 (es) Anticuerpos triespecificos o tetraespecificos
RU2011143905A (ru) ПОЛИСПЕЦИФИЧНЫЕ АНТИТЕЛА, ВКЛЮЧАЮЩИЕ АНТИТЕЛА ПОЛНОЙ ДЛИНЫ И ОДНОЦЕПОЧЕЧНЫЕ ФРАГМЕНТЫ Fab
JP2016538240A5 (enExample)
JP2019502694A5 (enExample)
JP2018033454A5 (enExample)